Emerging Role of NLRP3 Inflammasome/Pyroptosis in Huntington's Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Aug 12

PMID 35955494

Authors

Emanuela Paldino

Francesca Romana Fusco

Affiliations

Soon will be listed here.

Abstract

Huntington's disease (HD) is a neurodegenerative disease characterized by several symptoms encompassing movement, cognition, and behavior. The mutation of the gene encoding for the huntingtin protein is the cause of HD. Mutant huntingtin interacts with and impairs the function of several transcription factors involved in neuronal survival. Although many mechanisms determining neuronal death have been described over the years, the significant role of inflammation has gained momentum in the last decade. Drugs targeting the elements that orchestrate inflammation have been considered powerful tools to treat HD. In this review, we will describe the data supporting inflammasome and NLRP3 as a target of therapeutics to fight HD, deepening the possible mechanisms of action underlying these effects.

Citing Articles

Mitochondrial modulation treating postoperative cognitive dysfunction neuroprotection via DRP1 inhibition by Mdivi1.

Ying J, Deng X, Du R, Ding Q, Tian H, Lin Y Sci Rep. 2024; 14(1):26155.

PMID: 39478015 PMC: 11525678. DOI: 10.1038/s41598-024-75548-1.

Neuroimmune pathways involvement in neurodegeneration of R6/2 mouse model of Huntington's disease.

Paldino E, Migliorato G, Fusco F Front Cell Neurosci. 2024; 18:1360066.

PMID: 38444595 PMC: 10912295. DOI: 10.3389/fncel.2024.1360066.

Design and Discovery of Novel NLRP3 Inhibitors and PET Imaging Radiotracers Based on a 1,2,3-Triazole-Bearing Scaffold.

Xu Y, Xu Y, Biby S, Kaur B, Liu Y, Bagdasarian F J Med Chem. 2023; 67(1):555-571.

PMID: 38150705 PMC: 11002996. DOI: 10.1021/acs.jmedchem.3c01782.

Mutant-Huntingtin Molecular Pathways Elucidate New Targets for Drug Repurposing.

Makeeva V, Dyrkheeva N, Lavrik O, Zakian S, Malakhova A Int J Mol Sci. 2023; 24(23).

PMID: 38069121 PMC: 10706709. DOI: 10.3390/ijms242316798.

The Impact of Neurotransmitters on the Neurobiology of Neurodegenerative Diseases.

Davis S, Cirincione A, Jimenez-Torres A, Zhu J Int J Mol Sci. 2023; 24(20).

PMID: 37895020 PMC: 10607327. DOI: 10.3390/ijms242015340.

References

Biber K, Moller T, Boddeke E, Prinz M . Central nervous system myeloid cells as drug targets: current status and translational challenges. Nat Rev Drug Discov. 2015; 15(2):110-24. DOI: 10.1038/nrd.2015.14. View

Meng L, Zhao P, Hu Z, Ma W, Niu Y, Su J . Nilotinib, A Tyrosine Kinase Inhibitor, Suppresses the Cell Growth and Triggers Autophagy in Papillary Thyroid Cancer. Anticancer Agents Med Chem. 2021; 22(3):596-602. DOI: 10.2174/1871520621666210402110331. View

Johnson W, Wilson-Delfosse A, Mieyal J . Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients. 2012; 4(10):1399-440. PMC: 3497002. DOI: 10.3390/nu4101399. View

Cookson B, Brennan M . Pro-inflammatory programmed cell death. Trends Microbiol. 2001; 9(3):113-4. DOI: 10.1016/s0966-842x(00)01936-3. View

Sawa A, Wiegand G, Cooper J, Margolis R, Sharp A, Lawler Jr J . Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med. 1999; 5(10):1194-8. DOI: 10.1038/13518. View

Mi Y, Gao X, Xu H, Cui Y, Zhang Y, Gou X . The Emerging Roles of Ferroptosis in Huntington's Disease. Neuromolecular Med. 2019; 21(2):110-119. DOI: 10.1007/s12017-018-8518-6. View

Yu H, Lin C, Tai W, Liu C, Shiau C, Chen K . Nilotinib induces autophagy in hepatocellular carcinoma through AMPK activation. J Biol Chem. 2013; 288(25):18249-59. PMC: 3689967. DOI: 10.1074/jbc.M112.446385. View

Ona V, Li M, Vonsattel J, ANDREWS L, Khan S, Chung W . Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature. 1999; 399(6733):263-7. DOI: 10.1038/20446. View

Caccamo A, Branca C, Piras I, Ferreira E, Huentelman M, Liang W . Necroptosis activation in Alzheimer's disease. Nat Neurosci. 2017; 20(9):1236-1246. DOI: 10.1038/nn.4608. View

10.

Block M, Hong J . Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans. 2007; 35(Pt 5):1127-32. DOI: 10.1042/BST0351127. View

11.

Bauer P, Goswami A, Wong H, Okuno M, Kurosawa M, Yamada M . Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat Biotechnol. 2010; 28(3):256-63. DOI: 10.1038/nbt.1608. View

12.

Albin R, Reiner A, Anderson K, Dure 4th L, Handelin B, Balfour R . Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann Neurol. 1992; 31(4):425-30. DOI: 10.1002/ana.410310412. View

13.

Liddelow S, Guttenplan K, Clarke L, Bennett F, Bohlen C, Schirmer L . Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017; 541(7638):481-487. PMC: 5404890. DOI: 10.1038/nature21029. View

14.

Martinon F, Mayor A, Tschopp J . The inflammasomes: guardians of the body. Annu Rev Immunol. 2009; 27:229-65. DOI: 10.1146/annurev.immunol.021908.132715. View

15.

Prerna K, Dubey V . Repurposing of FDA-approved drugs as autophagy inhibitors in tumor cells. J Biomol Struct Dyn. 2021; 40(13):5815-5826. DOI: 10.1080/07391102.2021.1873862. View

16.

Nucifora Jr F, Sasaki M, Peters M, Huang H, Cooper J, Yamada M . Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science. 2001; 291(5512):2423-8. DOI: 10.1126/science.1056784. View

17.

Paldino E, DAngelo V, Sancesario G, Fusco F . Pyroptotic cell death in the R6/2 mouse model of Huntington's disease: new insight on the inflammasome. Cell Death Discov. 2020; 6:69. PMC: 7395807. DOI: 10.1038/s41420-020-00293-z. View

18.

Kuo K, Mrkobrada M . A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia. Hemoglobin. 2014; 38(6):409-21. DOI: 10.3109/03630269.2014.965781. View

19.

Giampa C, Middei S, Patassini S, Borreca A, Marullo F, Laurenti D . Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease. Eur J Neurosci. 2009; 29(5):902-10. DOI: 10.1111/j.1460-9568.2009.06649.x. View

20.

Chen K, Hua K, Tsai F, Lin T, Cheng C, Yang D . A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease. J Neuroinflammation. 2022; 19(1):56. PMC: 8882273. DOI: 10.1186/s12974-022-02419-9. View